FBLG Valuation

Fibrobiologics Inc

Add to Watchlist

Advanced Chart

0.590

-0.03(-4.837%)1D

Overview
Forecast
Valuation
Earnings

FBLG Relative Valuation

FBLG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FBLG is overvalued; if below, it's undervalued.

Historical Valuation

Fibrobiologics Inc (FBLG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -10.30. The fair price of Fibrobiologics Inc (FBLG) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.59

Fair

-1.39

Trailing

Forward

0.00

EV/EBITDA

Fibrobiologics Inc. (FBLG) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-1.38

EV/EBIT

Fibrobiologics Inc. (FBLG) has a current EV/EBIT of -1.38. The 5-year average EV/EBIT is -10.07. The thresholds are as follows: Strongly Undervalued below -31.58, Undervalued between -31.58 and -20.82, Fairly Valued between 0.69 and -20.82, Overvalued between 0.69 and 11.45, and Strongly Overvalued above 11.45. The current Forward EV/EBIT of -1.38 falls within the Historic Trend Line -Fairly Valued range.

0.00

Fibrobiologics Inc. (FBLG) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

Fibrobiologics Inc. (FBLG) has a current P/OCF of 0.00. The 5-year average P/OCF is -6.12. The thresholds are as follows: Strongly Undervalued below -24.13, Undervalued between -24.13 and -15.12, Fairly Valued between 2.89 and -15.12, Overvalued between 2.89 and 11.89, and Strongly Overvalued above 11.89. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.17

P/FCF

Fibrobiologics Inc. (FBLG) has a current P/FCF of -1.17. The 5-year average P/FCF is -5.95. The thresholds are as follows: Strongly Undervalued below -22.23, Undervalued between -22.23 and -14.09, Fairly Valued between 2.19 and -14.09, Overvalued between 2.19 and 10.34, and Strongly Overvalued above 10.34. The current Forward P/FCF of -1.17 falls within the Historic Trend Line -Fairly Valued range.

Fibrobiologics Inc (FBLG) has a current Price-to-Book (P/B) ratio of 28.04. Compared to its 3-year average P/B ratio of 16.08 , the current P/B ratio is approximately 74.37% higher. Relative to its 5-year average P/B ratio of 16.08, the current P/B ratio is about 74.37% higher. Fibrobiologics Inc (FBLG) has a Forward Free Cash Flow (FCF) yield of approximately -61.91%. Compared to its 3-year average FCF yield of -19.84%, the current FCF yield is approximately 212.01% lower. Relative to its 5-year average FCF yield of -19.84% , the current FCF yield is about 212.01% lower.

28.04

P/B

Median3y

16.08

Median5y

16.08

-61.91

FCF Yield

Median3y

-19.84

Median5y

-19.84

Competitors Valuation Multiple

The average P/S ratio for FBLG's competitors is 7.40, providing a benchmark for relative valuation. Fibrobiologics Inc Corp (FBLG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Akari Therapeutics PLC

Loss

24.79M

ENLV.O

Enlivex Therapeutics Ltd

CytoMed Therapeutics Ltd

44.43

23.10M

APUS.A

Apimeds Pharmaceuticals US Inc

Loss

23.01M

Performance Decomposition

Market capitalization of FBLG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of FBLG in the past 1 year is driven by Unknown.